R3HDM1 and cancer: These pathways are negatively enriched in most cancer patients with high R3HDM1 expression levels, including CESC, DLBC, ESCA, GBM, HNSC, LAML, LGG, LUSC, MESO, OV, PCPG, SARC, and UCS.